DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.06 Bil PE Ratio: 48.19 PB Ratio: 15.88 GF Score: 74/100

DexCom Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 04:00PM GMT
Robert Justin Marcus
JP Morgan Chase & Co, Research Division - Analyst

Good morning, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Robbie Marcus, the med tech analyst.

I'm very happy to have DexCom here to kick off the medical device track here at the conference. Proud to introduce Kevin Sayer, President, Chairman and CEO of DexCom.

Kevin R. Sayer
DexCom, Inc. - Executive Chairman, CEO & President

Thank you very much, Robbie. It's a pleasure to be here today. Actually, I think this is the fifth time I've been here as the CEO of DexCom to make this presentation. I'm pretty excited to start the presentation off the same way I've started the other 5. 2019 was a record year for DexCom. As CGM continues to drive therapy and the momentum grows, our business continues to perform beyond our expectations.

Let's talk a bit about the 2019 numbers. Revenue for 2019, for instance, can be approximately $1.47 billion. That's 42% over our 2018 numbers. In the fourth quarter, our estimated revenues were approximately $457 million,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot